X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
THR-149 is a novel plasma kallikrein (PKal) inhibitor which is being evaluated under phase 2 clinical trials for the treatment of diabetic macular edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Financing September 18, 2023
Details:
The financing from the agreement will enable Oxurion to progress the Phase 2, Part B KALAHARI trial of THR-149, a potent PKal inhibitor, in Diabetic Macular Edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2023
Details:
The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 11, 2023
Details:
Under the agreement, VIB acquired Oxurion's preclinical oncology asset and will use the upfront in the development of THR-149, being evaluated in a Phase 2 clinical trial as a potential treatment for of diabetic macular edema.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: VIB
Deal Size: $32.4 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement July 24, 2023
Details:
The net proceeds will be used to fund the Phase 2, KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $22.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2023
Details:
THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. THR-149 is currently being evaluated for Diabetic Macular Edema.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. Through the inhibition of the kallikrein-kinin system (KKS), THR-149 prevents the induction of retinal vascular permeability and inflammation.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
The financing will be used to progress towards finishing patient recruitment for the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149 for treating the up to 50% of patients with diabetic macular edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $22.4 million Upfront Cash: Undisclosed
Deal Type: Financing May 22, 2023
Details:
The financing will be used to fund the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Endocrinology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $22.8 million Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
